NASDAQ$ERAS
Erasca Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported business updates and financial results for Q1 2024.
Erasca reported compelling survival data from a pooled analysis of mature data for naporafenib plus trametinib in patients with NRASm melanoma, which showed a near doubling of median overall survival. The company also strengthened its balance sheet with a $45 million private placement financing.
- Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma.
- Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors.
- Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026.
- Expects several data readouts across clinical programs, including naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1).
Headline financials
Revenue & EPS history
Erasca · Revenue · Quarterly
$84K
Forward guidance
Erasca expects initial Phase 1b combination data for SEACRAFT-1 between the second and fourth quarters of 2024, Phase 1b combination data for HERKULES-3 in the second quarter of 2024, and initial Phase 1 monotherapy data for THUNDERBBOLT-1 in 2024. The company also expects to initiate its pivotal SEACRAFT-2 trial in the second quarter of 2024.
Tailwinds
- Initial Phase 1b combination data for SEACRAFT-1 expected between the second and fourth quarters of 2024
- Phase 3 trial initiation expected in the second quarter of 2024
- Phase 1b combination data for HERKULES-3 expected in the second quarter of 2024
- Initial Phase 1 monotherapy data for THUNDERBBOLT-1 expected in 2024
- Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2024
+1.1%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+1.3%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+11.0%
Q3 2022
Best reaction
-10.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | +1.0% | +32.1% | |
| Q4 2025 | -4.3% | -7.8% | +16.1% | |
| Q3 2025 | -4.2% | +7.9% | +35.8% | |
| Q1 2025 | -4.0% | -5.8% | +9.3% | |
| Q4 2024 | +6.0% | -8.2% | +25.0% | |
| Q3 2024 | -8.4% | -14.1% | -15.4% | |
| Q2 2024 | +8.3% | +16.7% | +27.9% | |
| Q1 2024 | -10.1% | -12.8% | +8.9% | |
| Q4 2023 | +4.0% | +9.1% | -4.5% | |
| Q3 2023 | -8.6% | -1.8% | -15.0% | |
| Q2 2023 | +10.6% | -3.2% | -0.8% | |
| Q1 2023 | -1.0% | -3.8% | -5.6% | |
| Q4 2022 | -2.7% | -5.8% | -3.8% | |
| Q3 2022 | +11.0% | +20.7% | -19.1% | |
| Q2 2022 | +2.5% | +4.4% | -10.8% | |
| Q1 2022 | +2.8% | +9.4% | -4.6% | |
| Q4 2021 | +9.1% | +8.1% | -9.7% | |
| Q3 2021 | +2.2% | -3.1% | -28.9% | |
| Q2 2021 | +4.8% | +8.9% | -12.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro